“…6 García et al conducted a multicentre retrospective study including 78 patients with ASUC failing either infliximab (n = 32) or cyclosporine (n = 46) to assess outcomes of third-line rescue therapy (45 infliximab, 17 cyclosporine, 13 tofacitinib and 3 ustekinumab). 7 During the median of 21 weeks, colectomy was performed in 29 patients (37%) with colectomy-free survival and corticosteroid-free clinical remission rates at week 52 of 58% and 20%, respectively. Adverse events were reported in 26 patients (33%), of whom two patients died and another two patients had a colonic perforation.…”